Should I Buy PACS? PACS 2026 Analysis

Should You Buy Pacs Group Inc (PACS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

34.180

1 Day change

-0.49%

52 Week Range

43.080

Analysis Updated At

2026/01/26

Pacs Group Inc (PACS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent acquisitions provide a solid foundation for growth. Despite short-term technical weakness, the long-term outlook remains favorable.

Technical Analysis

The stock is currently oversold with an RSI of 19.523, indicating a potential rebound opportunity. However, the MACD histogram is -1.221 and negatively expanding, suggesting bearish momentum. The stock is trading near its S1 support level of 35.36, which could act as a potential floor for the price.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate bullish sentiment in the options market, with significantly higher call activity compared to puts.

Technical Summary

Sell

Buy

Positive Catalysts

Strong financial performance in Q3 2025 with revenue up 31.01% YoY, net income up 235.51% YoY, and EPS up 220.00% YoY.
Recent acquisition of three post-acute care facilities, adding 230 beds and expanding market share.
Analysts maintain a Buy or Overweight rating with price targets ranging from $40 to $44, reflecting confidence in the company's growth potential.

Neutral/Negative Catalysts

Short-term bearish technical indicators, including a negatively expanding MACD and convergence of moving averages.
Outstanding regulatory and legal issues, though fundamentals remain strong.

Financial Performance

In Q3 2025, Pacs Group reported robust financial growth: Revenue increased by 31.01% YoY to $1.34 billion, net income surged by 235.51% YoY to $52.4 million, EPS grew by 220.00% YoY to 0.32, and gross margin improved by 53.95% YoY to 14.04%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are optimistic about Pacs Group, with recent ratings from Truist, UBS, and JPMorgan maintaining Buy or Overweight recommendations. Price targets have been adjusted to reflect current valuations, ranging from $40 to $44, highlighting confidence in the company's business model and growth prospects.

5 Analyst Rating

Wall Street analysts forecast PACS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PACS is 42.6 USD with a low forecast of 40 USD and a high forecast of 47 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 34.350

Low

Averages

42.6

High

Current: 34.350

Low

Averages

42.6

High

Truist

David MacDonald

Buy

downgrade

$48 -> $40

AI Analysis

2026-01-05

Reason

Truist

David MacDonald

Price Target

$48 -> $40

AI Analysis

2026-01-05

downgrade

Buy

Reason

Truist analyst David MacDonald lowered the firm's price target on Pacs Group to $40 from $48 and keeps a Buy rating on the shares. Pacs Group is well-positioned into 2026 following the November conclusion of the Audit Committee investigation with committee recommendations having been or being implemented, the analyst tells investors in a research note.

UBS

NULL -> Buy

downgrade

$50 -> $42

2025-12-18

Reason

UBS

Price Target

$50 -> $42

2025-12-18

downgrade

NULL -> Buy

Reason

UBS resumed coverage of Pacs Group with a Buy rating with a price target of $42, down from $50. Pacs is well-positioned to take advantage of industry tailwinds that include an aging U.S. population, shifts to lower cost site of care settings, and a fragmented industry that provides ample acquisition opportunities of low performing facilities, the analyst tells investors in a research note. The current valuation reflects a few outstanding regulatory and legal issues and fundamentals are holding strong, the firm adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PACS

Unlock Now

PACS Should I Buy

PACS Should I Buy

Should You Buy Pacs Group Inc (PACS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch